SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-24-011310
Filing Date
2024-03-26
Accepted
2024-03-26 16:30:43
Documents
14
Period of Report
2024-03-04
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 42142
2 ex3-3.htm EX-3.3 11856
  Complete submission text file 0001493152-24-011310.txt   232604

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE mymd-20240304.xsd EX-101.SCH 3003
4 XBRL LABEL FILE mymd-20240304_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE mymd-20240304_pre.xml EX-101.PRE 22351
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 3854
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36268 | Film No.: 24784057
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)